Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine

Experimental Lung Research

Volumn 34, Issue 10, 2008, Pages 681-693

  Sadofsky, Laura R ^a   Campi, Barbara ^b   Trevisani, Marcello ^b   Compton, Steven J ^a   Morice, Alyn H ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Antihistamines; Chlorpheniramine; Dexbrompheniramine; Dipheniramine; Fexofenadine; TRPV1

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIUM; CAPSAICIN; CHLORPHENIRAMINE; DEXBROMPHENIRAMINE; VANILLOID RECEPTOR 1;

ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; CELL LINE; CELL STRAIN HEK293; CELL STRAIN PRO5; EVOKED RESPONSE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPINAL GANGLION; SPRAGUE DAWLEY RAT;

ANIMALS; BROMPHENIRAMINE; CALCIUM; CALCIUM CHANNELS; CAPSAICIN; CELL LINE; CHLORPHENIRAMINE; HISTAMINE ANTAGONISTS; HUMANS; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRPV CATION CHANNELS;

EID: 57749104797     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140802339623     Document Type: Article

References (31)

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997; 389:816-824.
2. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998;21:531-543.
3. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U: Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000;97:6155-6160.
4. Morice AH: Inhalation cough challenge in the investigation of the cough reflex and antitussives. Pulm Pharmacol. 1996;9:281-284.
5. Laude EA, Higgins KS, Morice AH: A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man. Pulm Pharmacol. 1993;6:171-175.
6. Morice AH, Geppetti P: Cough. 5: The type 1 vanilloid receptor: a sensory receptor for cough, Thorax. 2004;59:257-258.
7. Gatti R, Andre E, Amadesi S, Dinh TQ, Fischer A, Bunnett NW, Harrison S, Geppetti P, Trevisani M: Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs. J Appl Physiol. 2006;101:506-511.
8. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P, Poe RH, Prakash UB, Pratter MR, Rubin BK: Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest. 1998;114:133S-181S.
9. Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, Kastelik JA,McGarvey LP, Smith JA, Tatar M, Widdicombe J: ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256-1276.
10. Mitchell JE, Campbell AP, New NE, Sadofsky LR, Kastelik JA, Mulrennan SA, Compton SJ, Morice AH: Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough. Exp Lung Res. 2005;31:295-306.
11. Compton SJ, Cairns JA, Palmer KJ, Al-Ani B, Hollenberg MD, Walls AF: A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem. 2000;275:39207-39212.
12. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M,Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, Bunnett NW: Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci. 2004;24:4300-4312.
13. Anderson GP: TRPV1 and cough, Thorax. 2004;59:730-731.
14. Inoue K, Koizumi S, Fuziwara S, Denda S, Denda M: Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun. 2002;291:124-129.
15. Denda M, Fuziwara S, Inoue K, Denda S, Akamatsu H, Tomitaka A, Matsunaga K: Immunoreactivity of VR1 on epidermal keratinocyte of human skin. Biochem Biophys Res Commun. 2001;285:1250-1252.
16. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A: Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. 2000;97:3655-3660.
17. Miyamoto R, Tokuda M, Sakuta T, Nagaoka S, Torii M: Expression and characterization of vanilloid receptor subtype 1 in human dental pulp cell cultures, J Endod. 2005;31:652-658.
18. Xin H, Tanaka H, Yamaguchi M, Takemori S, Nakamura A, Kohama K: Vanilloid receptor expressed in the sarcoplasmic reticulum of rat skeletal muscle. Biochem Biophys Res Commun. 2005;332:756-762.
19. Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, Dineley KE, Watkins S, Reynolds IJ, Caterina MJ: Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci U S A. 2001;98:13396-13401.
20. Birder LA: TRPs in bladder diseases. Biochim Biophys Acta. 2007;1772:879-884.
21. Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P: Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001;357:1338-1339.
22. Groneberg DA, Niimi A, Dinh QT, Cosio B, Hew M, Fischer A, Chung KF: Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med. 2004;170:1276-1280.
23. Bevan S, Hothi S, Hughes G, James IF, Rang HP, Shah K, Walpole CS, Yeats JC: Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol. 1992;107:544-552.
24. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S,Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB: Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther. 2007;321:1183-1192.
25. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB: Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist, Neuropharmacology. 2004;46:133-149.
26. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, Gunthorpe MJ, Davis JB: Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006;16:3287-3291.
27. Wahl P, Foged C, Tullin S, Thomsen C: Iodo-resiniferatoxin. a new potent vanilloid receptor antagonist. Mol Pharmacol. 2001;59:9-15.
28. Docherty RJ, Yeats JC, Piper AS: Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol. 1997;121:1461-1467.
29. Liu L, Simon SA: Capsazepine, a vanilloid receptor antagonist. inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia, Neurosci Lett. 1997;228:29-32.
30. Shimizu I, Iida T, Horiuchi N, Caterina MJ: 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther. 2005;314:1378-1385.
31. Bhattacharya A, Scott BP, Nasser N, Ao H, Maher MP, Dubin AE, Swanson DM, Shankley NP, Wickenden AD, Chaplan SR: Pharmacology and antitussive efficacy of 4-(3-trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a TRPV1 antagonist in guinea pigs. J Pharmacol Exp Ther. 2007;323:665-674.